Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
AbbVie said on September 22 that it has won Japanese regulatory approval for new dosage forms of its psoriasis treatment Skyrizi (risankizumab) - 150 mg pre-filled syringe and auto-injector versions - which will enable a single injection for each treatment.…
To read the full story
Related Article
- AbbVie Files New Dosage Forms for Skyrizi in Japan
September 29, 2020
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





